Journal of Clinical Oncology - Ocak 2011

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Carmen J. Allegra,  Greg Yothers,  Michael J. O'Connell,  Saima Sharif,  Nicholas J. Petrelli,  Linda H. Colangelo,  James N. Atkins,  Thomas E. Seay, Louis Fehrenbacher,  Richard M. Goldberg,  Seamus O'Reilly,  Luis Chu,  Catherine A. Azar,  Samia Lopa,  and Norman Wolmark
[Abstract]


Diabetes Mellitus and Breast Cancer Outcomes: A Systematic Review and Meta-Analysis
Kimberly S. Peairs, Bethany B. Barone, Claire F. Snyder, Hsin-Chieh Yeh, Kelly B. Stein, Rachel L. Derr, Frederick L. Brancati, and Antonio C. Wolff
[Abstract]


Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Daniela Matei, Michael W. Sill, Heather A. Lankes, Koen DeGeest, Robert E. Bristow, David Mutch, S. Diane Yamada, David Cohn, Valerie Calvert, John Farley, Emanuel F. Petricoin, and Michael J. Birrer
[Abstract]


Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
David Miles, Nadia Harbeck, Bernard Escudier, Herbert Hurwitz, Leonard Saltz, Eric Van Cutsem, Jim Cassidy, Barbara Mueller, and Florin Sirzén.
[Abstract]


Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated Anemia
David P. Steensma, Jeff A. Sloan, Shaker R. Dakhil, Robert Dalton, Stephen P. Kahanic, Diane J. Prager, Philip J. Stella, Kendrith M. Rowland, Jr., Paul J. Novotny, and Charles L. Loprinzi
[Abstract]


Impact of Comorbidity on Chemotherapy Use and Outcomes in Solid Tumors: A Systematic Review
Linda Lee, Winson Y. Cheung, Esther Atkinson, and Monika K. Krzyzanowska
[Abstract]


Volume 29, Issue 2 - January 10, 2011


Subcutaneous Compared With Intravenous Administration of Amifostine in Patients With Head and Neck Cancer Receiving Radiotherapy: Final Results of the GORTEC2000-02 Phase III Randomized Trial
Etienne Bardet, Laurent Martin, Gilles Calais, Marc Alfonsi, Nasr Eddine Feham, Claude Tuchais, Pierre Boisselier, Bernadette Dessard-Diana, Sok-Hun Seng, Pascal Garaud, Anne Aupérin, and Jean Bourhis
[Abstract]

Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
Martin Kocher, Riccardo Soffietti, Ufuk Abacioglu, Salvador Villà, Francois Fauchon, Brigitta G. Baumert, Laura Fariselli, Tzahala Tzuk-Shina, Rolf-Dieter Kortmann, Christian Carrie, Mohamed Ben Hassel, Mauri Kouri, Egils Valeinis, Dirk van den Berge, Sandra Collette, Laurence Collette, and Rolf-Peter Mueller
[Abstract]


Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Albert Lai, Anh Tran, Phioanh L. Nghiemphu, Whitney B. Pope, Orestes E. Solis, Michael Selch, Emese Filka, William H. Yong, Paul S. Mischel, Linda M. Liau, Surasak Phuphanich, Keith Black, Scott Peak, Richard M. Green, Cynthia E. Spier, Tatjana Kolevska, Jonathan Polikoff, Louis Fehrenbacher, Robert Elashoff, and Timothy Cloughesy
[Abstract]


Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
Vicente Valero, John Forbes, Mark D. Pegram, Tadeusz Pienkowski, Wolfgang Eiermann, Gunter von Minckwitz, Henri Roche, Miguel Martin, John Crown, John R. Mackey, Pierre Fumoleau, Janusz Rolski, Zrinka Mrsic-Krmpotic, Agnieszka Jagiello-Gruszfeld, Alessandro Riva, Marc Buyse, Henry Taupin, Guido Sauter, Michael F. Press, and Dennis J. Slamon
[Abstract]


Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials
Bostjan Seruga, Lynn Sterling, Lisa Wang, and Ian F. Tannock
[Abstract]


Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study
Rochelle Bagatell, Wendy B. London, Lars M. Wagner, Stephan D. Voss, Clinton F. Stewart, John M. Maris, Cynthia Kretschmar, and Susan L. Cohn
[Abstract]


Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
Jalid Sehouli, Dirk Stengel, Philipp Harter, Christian Kurzeder, Antje Belau, Thomas Bogenrieder, Susanne Markmann, Sven Mahner, Lothar Mueller, Ralf Lorenz, Andreas Nugent, Jochen Wilke, Andreas Kuznik, Gabriele Doering, Arthur Wischnik, Harald Sommer, Hans-Gerd Meerpohl, Willibald Schroeder, Werner Lichtenegger, and Guelten Oskay-Oezcelik
[Abstract]


Volume 29, Issue 3 - January 20, 2011


Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study
Michael Andersson, Elisabeth Lidbrink, Karsten Bjerre, Erik Wist, Kristin Enevoldsen, Anders B. Jensen, Per Karlsson, Ulla B. Tange, Peter G. Sørensen, Susanne Møller, Jonas Bergh, and Sven T. Langkjer
[Abstract]


Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group
Study RTOG 0214 Elizabeth M. Gore, Kyounghwa Bae, Stuart J. Wong, Alexander Sun, James A. Bonner, Steven E. Schild, Laurie E. Gaspar, Jeffery A. Bogart, Maria Werner-Wasik, and Hak Choy
[Abstract]


Phase III Trial of Prophylactic Cranial Irradiation Compared With Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Neurocognitive and Quality-of-Life Analysis
Alexander Sun,  Kyounghwa Bae,  Elizabeth M. Gore,  Benjamin Movsas,  Stuart J. Wong,  Christina A. Meyers,  James A. Bonner,  Steven E. Schild,  Laurie E. Gaspar,  Jeffery A. Bogart,  Maria Werner-Wasik,  and Hak Choy
[Abstract]


Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy  
Robert Jotte,  Paul Conkling,  Craig Reynolds,  Matthew D. Galsky,  Leonard Klein,  James F. Fitzgibbons,  Richard McNally,  Markus F. Renschler,  and Jennifer W. Oliver
[Abstract]



Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care—SAKK 33/99 
Jakob R. Passweg,  Aristoteles A.N. Giagounidis,  Mathew Simcock,  Carlo Aul,  Christiane Dobbelstein,  Michael Stadler,  Gert Ossenkoppele,  Wolf-Karsten Hofmann,  Kristina Schilling,  André Tichelli,  and Arnold Ganser
[Abstract]